|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Royalties | |||||
| Product sales, net | |||||
| Revenues under collaborative agreements | |||||
| Total revenues | |||||
| Operating expenses | |||||
| Cost of sales | |||||
| Amortization of intangibles | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Impairment of intangible asset | |||||
| Acquired in-process research and development expense | |||||
| Total operating expenses | |||||
| Operating income | |||||
| Other income (expense) | |||||
| Investment and other income, net | |||||
| Inducement expense related to convertible notes | |||||
| Contingent liability fair value measurement gain | |||||
| Interest expense | |||||
| Income before income tax expense | |||||
| Income tax expense | |||||
| Net income | |||||
| Earnings per share | |||||
| Basic (usd per share) | |||||
| Diluted (usd per share) | |||||
| Weighted average common shares outstanding | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...
